(Q35145255)

6 August 2017

title

Impact of a group-based model of disease management for headache (English)

1 reference

6 August 2017

1 reference

Morris Maizels

1

1 reference

6 August 2017

Valerie Saenz

series ordinal

2

1 reference

6 August 2017

Jonathan Wirjo

series ordinal

3

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

43

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

621-627

1 reference

Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Migraine diagnosis and treatment: results from the American Migraine Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Headache evaluation and treatment by primary care physicians in an emergency department in the era of triptans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Treatment of Acute Migraine With Subcutaneous Sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2003.03104.X

10.1046/J.1526-4610.2003.03104.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference